PMID- 31627041
OWN - NLM
STAT- MEDLINE
DCOM- 20200723
LR  - 20200723
IS  - 1872-6844 (Electronic)
IS  - 0920-1211 (Linking)
VI  - 157
DP  - 2019 Nov
TI  - Levetiracetam in genetic generalized epilepsy: A prospective unblinded 
      active-controlled trial.
PG  - 106214
LID - S0920-1211(19)30372-9 [pii]
LID - 10.1016/j.eplepsyres.2019.106214 [doi]
AB  - PURPOSE: To compare the efficacy and tolerability of levetiracetam (LEV) versus 
      valproate (VPA) monotherapy in adults with genetic generalized tonic-clonic 
      seizures alone (GTCS) and juvenile myoclonic epilepsy (JME). METHODS: This study 
      was an open-label, active-controlled trial with a two-parallel-group design. 
      Outcome measures including withdrawal rate and seizure freedom rate at 26th weeks 
      and time to withdrawal, and time to first seizure were compared between LEV and 
      VPA groups. Furthermore, tolerability and development of adverse events (AEs) 
      were investigated and analyzed. RESULTS: One hundred and three patients enrolled 
      the study. 71.1% of patients in LEV group and 29.3% in VPA group were female. By 
      the end of 26(th) week, seizure freedom rate and withdrawal rate were 88.9% and 
      8.9% in LEV group and 86.2% and 10.3% in VPA group with no significant 
      difference. Time to first seizure was longer in VPA group (p = 0.32) and time to 
      withdrawal favored LEV (p = 0.51). At least one AE was reported in 37.7% of 
      patients in LEV group and 55.1% in VPA group. The most common AEs were 
      psychiatric symptoms and dizziness in those on LEV and weight gain and dyspepsia 
      in VPA group. CONCLUSION: LEV has similar efficacy and acceptable safety in 
      comparison to VPA in short-term treatment of patients with genetic GTCS and JME, 
      and it could be considered as an alternative to VPA particularly in women of 
      reproductive age.
CI  - Copyright (c) 2019 Elsevier B.V. All rights reserved.
FAU - Tabrizi, Nasim
AU  - Tabrizi N
AD  - Neurology department, Mazandaran University of medical sciences, Sari, Iran. 
      Electronic address: nasimtabrizi@gmail.com.
FAU - Zarvani, Ashraf
AU  - Zarvani A
AD  - Neurology department, Mazandaran University of medical sciences, Sari, Iran.
FAU - Rezaei, Parisa
AU  - Rezaei P
AD  - Neurology department, Mazandaran University of medical sciences, Sari, Iran.
FAU - Cheraghmakani, Hamed
AU  - Cheraghmakani H
AD  - Neurology department, Mazandaran University of medical sciences, Sari, Iran.
FAU - Alizadeh-Navaei, Reza
AU  - Alizadeh-Navaei R
AD  - Gastrointestinal Cancer Research Center, Mazandaran University of Medical 
      Sciences, Sari, Iran.
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
DEP - 20191003
PL  - Netherlands
TA  - Epilepsy Res
JT  - Epilepsy research
JID - 8703089
RN  - 0 (Anticonvulsants)
RN  - 44YRR34555 (Levetiracetam)
RN  - 614OI1Z5WI (Valproic Acid)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anticonvulsants/*therapeutic use
MH  - Epilepsy, Generalized/*drug therapy/genetics
MH  - Female
MH  - Humans
MH  - Levetiracetam/*therapeutic use
MH  - Male
MH  - Myoclonic Epilepsy, Juvenile/*drug therapy/genetics
MH  - Prospective Studies
MH  - Treatment Outcome
MH  - Valproic Acid/*therapeutic use
MH  - Young Adult
OTO - NOTNLM
OT  - Genetic generalized epilepsy
OT  - Levetiracetam
OT  - Treatment
OT  - Valproate
EDAT- 2019/10/19 06:00
MHDA- 2020/07/24 06:00
CRDT- 2019/10/19 06:00
PHST- 2019/06/28 00:00 [received]
PHST- 2019/09/29 00:00 [revised]
PHST- 2019/10/02 00:00 [accepted]
PHST- 2019/10/19 06:00 [pubmed]
PHST- 2020/07/24 06:00 [medline]
PHST- 2019/10/19 06:00 [entrez]
AID - S0920-1211(19)30372-9 [pii]
AID - 10.1016/j.eplepsyres.2019.106214 [doi]
PST - ppublish
SO  - Epilepsy Res. 2019 Nov;157:106214. doi: 10.1016/j.eplepsyres.2019.106214. Epub 
      2019 Oct 3.